
US-based Endece, LLC manufactures and processes pharmaceutical drugs for human and veterinary use.
Founded in the United States, Endece, LLC is dedicated to the discovery and development of pharmaceutical drugs for both human and veterinary use. The company's core mission is to create treatments that halt disease progression, restore function, and improve quality of life. Endece's flagship product, NDC-1308, is a novel therapeutic designed to treat neurodegenerative diseases such as Multiple Sclerosis by inducing remyelination and inhibiting demyelination, setting it apart from other MS drugs on the market.
Notable figures affiliated with Endece include Dr. James Yarger, Ph.D., who serves as President. The company has garnered attention for its innovative approach to treating neurodegenerative diseases, particularly through the development of NDC-1308. This drug's unique mechanism-of-action has positioned Endece as a significant player in the pharmaceutical industry, contributing to advancements in medical treatments for debilitating conditions.

Endogenx

Endevica Bio
endevicabio.com

NeuroGenetic Pharmaceuticals
Caden Biosciences

Cadenza Bio
cadenza.bio
Endlyz Therapeutics

Zocere
zocere.com

CuraSen Therapeutics
curasen.com

Endosphere

Neurodon
neurodon.net

Adenios

Cerevance
cerevance.com

Ensysce Biosciences
ensysce.com

Genendeavor
genendeavor.com
GlobeStar Therapeutics
Companies similar to Endece include Endogenx, Endevica Bio, NeuroGenetic Pharmaceuticals and Caden Biosciences.
Endece was founded in 2006.
Endece's headquarters is located in Mequon, WI, US.
Endece's most recent funding round was for $1.2M (USD) in July 2011.
As of Jul 20, 2011, Endece has raised a total of $7.4M (USD).
Endece has 5 employees as of Feb 4, 2024.